Comparable stake leader
Lantheus Holdings, Inc.
SEC ownership of Radiopharm Theranostics Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001949257.
Disclosed value leader
REGAL PARTNERS HOLDINGS PTY LTD
Comparable rows
4/16
Latest evidence
19 Oct 2026
- Public ticker
- RADX on Nasdaq, RDPTF on OTC
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Lantheus Holdings, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 16
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Lantheus Holdings, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
19 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001949257
- Issuer location
- Carlton Vic
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Radiopharm Theranostics Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lantheus Holdings, Inc.
Disclosed value leader
REGAL PARTNERS HOLDINGS P...
Comparable rows
4/16
Latest evidence
19 Oct 2026
13D/G
13F
3/4/5
Lead comparable stake: 17%
12 rows are not safely comparable across share classes.
13D/G row: Lantheus Holdings, Inc.
Showing 1-8 of 16 holder rows.
Quick read
Lantheus Holdings, Inc. leads the comparable SEC ownership view at 17%.
4 of 16 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lantheus Holdings, Inc.'s linked filing trail.
Comparable ownership
Top 4
Lantheus Holdings, Inc.
17%
REGAL PARTNERS HOLDINGS PTY LTD
9%
JPMORGAN CHASE & CO
4%
Regal Partners Funds Management P...
3.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 16 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc. |
13D/G
Lantheus Omega, LLC
|
17%
Reported 13D/G
· 28 Jul 2026
|
—
792,958,513 shares
|
$0 | 28 Jul 2026 |
| REGAL PARTNERS HOLDINGS PTY LTD |
13D/G
Regal Partners Holdings Pty Limited
|
9%
Reported 13D/G
· 31 Dec 2025
|
$1,362,952,390
320,694,680 shares
|
+$629,253,691 | 31 Dec 2025 |
| JPMORGAN CHASE & CO |
13D/G
|
4%
Reported 13D/G
· 31 Dec 2025
|
—
145,679,951 shares
|
$0 | 31 Dec 2025 |
| Regal Partners Funds Management Pty Ltd |
13D/G
Regal Partners Funds Management Pty Limited
|
3.3%
Reported 13D/G
· 30 Sep 2026
|
$326,850,041
157,139,443 shares
|
$0 | 30 Sep 2026 |
| Stonepine Capital Management, LLC |
13F
Company
|
—
denominator unverified
|
$670,500
51,000,000 shares
|
— | 30 Jun 2026 |
| HSBC HOLDINGS PLC |
13F
Company
|
—
denominator unverified
|
$253,727
62,188 shares
|
— | 30 Jun 2026 |
| Regal Partners Ltd |
13F
Company
|
—
denominator unverified
|
$168,178
40,138 shares
|
— | 30 Jun 2026 |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
Company
|
—
denominator unverified
|
$83,800
20,000 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 29 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-8 of 8 reporting-owner rows connected to Radiopharm Theranostics Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
8
Largest Forms 3/4/5 holder
Bruce Michael Goodwin
Net 12M change
$0
Latest report
19 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Bruce Michael Goodwin | Director | Mixed | 18 Mar 2026 | |||
| Hester Denise Larkin | Director | Mixed | 18 Mar 2026 | |||
| Riccardo Canevari | Managing Director and CEO, Director | Mixed | 18 Mar 2026 | |||
| Ian Lawrence Turner | Director | Mixed | 18 Mar 2026 | |||
| Noel Donnelly | Director | Mixed | 18 Mar 2026 | |||
| Aaron James Laurita | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Paul Hopper | Director | Mixed | 18 Mar 2026 | |||
| Dimitris Voliotis | Chief Medical Officer | Mixed | 19 Oct 2026 |
Recent insider transactions for Radiopharm Theranostics Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Dimitris Voliotis | RADX | Option (Right to buy) | Award | 20,591,333 | 10,295,667 | 19 Oct 2026 | Direct |
* marks a reported price that did not pass the local price check.